United Therapeutics CORP Form 4 insider transactions

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt exercised options and sold shares under a pre-arranged 10b5-1 trading plan.

EVP and General Counsel Paul Mahon exercised 8,300 stock options and sold the resulting shares under a 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock, acquired through stock option exercises, as part of a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving common stock and stock options on April 10, 2026.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock on April 9, 2026, pursuant to a Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock and stock options on April 8, 2026, executed under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on April 7, 2026, executed under a 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock on April 6, 2026, as part of a pre-arranged trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock on April 6, 2026, under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported significant stock transactions on April 2, 2026, executed under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the exercise of stock options and sale of 10,000 shares of common stock on April 2, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a series of transactions involving the exercise of stock options and sale of common stock on April 1, 2026, under a 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported significant transactions involving common stock and stock options on March 31, 2026.

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, executed a pre-arranged 10b5-1 plan, exercising stock options and selling common stock.

United Therapeutics CFO and Treasurer James Edgemond exercised stock options and subsequently sold common stock shares totaling 7,986 under a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Christopher Causey executed a pre-planned sale of 1,300 common shares following the exercise of stock options.

United Therapeutics' Chairperson and CEO, Martine A. Rothblatt, exercised stock options and subsequently sold shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics' CFO and Treasurer, James Edgemond, exercised stock options and subsequently sold a significant portion of the acquired shares under a Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold resulting shares totaling 9,500 under a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Tommy G Thompson exercised stock options and subsequently sold a portion of his common stock holdings on March 26, 2026.

United Therapeutics' Chairperson and CEO, Martine A. Rothblatt, exercised stock options and sold shares totaling 9,500 under a pre-arranged 10b5-1 trading plan.

United Therapeutics CFO James Edgemond exercised stock options and sold a portion of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics' Chairperson and CEO, Martine A. Rothblatt, executed pre-planned stock option exercises and subsequent sales of common stock on March 23, 2026.

United Therapeutics Director Judy D. Olian sold 200 shares of common stock for $530 per share under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, executed a pre-arranged sale of 9,500 common shares following an option exercise.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold resulting shares under a pre-arranged 10b5-1 trading plan.